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Abstract
Background: Overexpression of Fra-1 in fibroblasts causes anchorage-independent cell growth
and oncogenic transformation. A high level of Fra-1 expression is found in various tumors and
tumorigenic cell lines, suggesting that Fra-1 may be involved in malignant progression. This study
aimed to investigate the significance of Fra-1 expression in breast carcinogenesis.
Methods: The expression of Fra-1 was investigated by immunohistochemistry in neoplastic breast
diseases ranging from benign fibroadenoma to very aggressive undifferentiated carcinoma. The
correlations of Fra-1 expression with other indicators of breast carcinoma prognosis (ER, PR and
ErbB2 receptors) were analyzed.
Results: All neoplastic breast tissues, either benign or malignant breast tissues, were nuclear
immunoreactive for Fra-1-recognizing antibody. The pattern of Fra-1 expression by benign
neoplastic cells was predominantly nuclear. However, the nuclear/cytoplasmic concomitant
immunoreactivity was observed in all types of breast carcinomas. A clear shift in Fra-1
immunoreactivity, from an exclusively nuclear to a simultaneous nuclear and cytoplasmic
localization was noticed in ~90% of breast carcinomas.
Conclusion: The overall expression, pattern and intensity of Fra-1 proteins were correlated with
breast oncogenesis. Overexpression of Fra-1, leading to a persistent high cytoplasmic
accumulation, may play a role in the process of breast carcinogenesis.
Background
Transcription factor AP-1 (activator protein 1) is thought
to play an important role in regulating the gene expres-
sion pattern in response to external stimuli [1-4]. It is
composed of transcription factors belonging to Jun and
Fos families [5,6]. In mammalian cells, three members of
the Jun family (c-Jun, JunB, and JunD) and four members
of the Fos family (c-Fos, FosB, Fra-1, Fra-2) have been
identified to date. These two family members can form
Jun/Jun homodimers or more stable Fos/Jun heterodim-
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ers, which bind to the palindromic TGA(C/G)TCA recog-
nition sequence, so-called 12-O-tetradecanoylphorbol-
13-acetate (TPA) response element (TRE) and activate the
gene transcription [7-9]. Since TRE-containing promoter
constructs were strongly activated by the tumor promoter
TPA and AP-1 proteins (c-Jun and c-Fos) [10], the AP-1
complex was implicated in carcinogenesis soon after dis-
covery.
In eukaryotic cells, extracellular stimuli cause a series of
intracellular signals that ultimately activate the proteins
binding to transcriptional control elements, selectively
regulating gene expression. Fos and Jun family members
participate at the end of signal transduction pathways [11-
14]. Stimulation with various growth factors and activated
oncogenes results in immediate transcriptional activation
of the c-Fos gene, accompanied with transient overexpres-
sion of c-Fos protein and formation of c-Jun/c-Fos het-
erodimers [15-17]. Whereas, Fra-1 expression is delayed
and more stable. In exponentially growing cells, Fra-1 pro-
tein is hyperphosphorylated and its expression elevated
[18].
All AP-1 proteins are characterized by a basic leucine-zip-
per region. As the transcription factors, c-Fos and FosB
proteins harbor a C-terminal transactivation domain, but
Fra-1 and Fra-2 lack this region [19,20]. Since Fra-1 and
Fra-2 were shown to inhibit c-Fos- and c-Jun-dependent
transactivation in a transient-transfection assay, it has
been proposed that these proteins act as negative regula-
tors, which limit the duration of the AP-1 response [21].
However, emerging evidence suggests an important role
for Fra-1 in cell motility, invasion, and progression of the
transformed state in several cell types [22-24]. The recent
data indicated that overexpressed Fra-1 in fibroblasts
causes anchorage-independent growth and oncogenic
transformation [10,25]. A high level of Fra-1 expression is
found in some tumors and tumorigenic cell lines [26-30].
These results suggested that Fra-1 might be involved in
malignant progression. However, few reports deal with
the expression and location of Fra-1 protein in human
breast tumor tissues.
In this study, we conducted retrospective study using 61
paraffin-embedded breast tumor tissues to investigate Fra-
1 expression by immunohistochemistry. The correlations
of Fra-1 with estrogen receptor (ER), progesterone recep-
tor (PR) and ErbB2 receptor status were analyzed in breast
cancer patients in order to further explore the role of Fra-
1 in the diagnosis of breast cancer.
Methods
Collection of Breast Tissue Samples
A total of 61 breast tissue specimens constituted by
fibroadenomas, hyperplastic adenosis/fibroadenomas,
ductal carcinomas, lobular carcinomas and other breast
carcinomas were collected at 307 Hospital (Beijing,
China) from patients undergoing surgery (Table 1). All
tumor tissue samples were fixed immediately after surgi-
cal removal in 10% buffered formalin and embedded in
paraffin.
Immunohistochemistry
Paraffin-embedded tissue was freshly cut (4 μm). The sec-
tions were dewaxed with xylene, and gradually hydrated
in a decreasing ethanol series ending in distilled water.
Endogenous peroxidase activity was quenched using 3%
hydrogen peroxide in distilled water for 5–10 minutes
and then washed in phosphate buffered saline (PBS)
before immunohistochemical staining. The Streptavidin-
Biotin method was used to detect Fra-1 expression. Anti-
gen retrieval was achieved using microwave heating in 1
mM EDTA (pH 9.0) at ~97°C for 20 minutes, followed by
a 20 minute cooldown period at room temperature. The
rabbit polyclonal antibody against the synthetic peptide
derived from residues 128–180 of human Fra-1
(ab22837, Abcam Lid. UK) at a concentration of 5 μg/ml
in PBS was applied for 60 minutes at 37°C or overnight at
4°C. The antibody is not able to detect the other members
of Fos family. After washing with PBS, sections were incu-
bated with biotinylated anti-rabbit antibody (Zhongshan
Co., Beijing, China) at 37°C for 15 minutes and washed
in PBS. Then the streptavidin peroxidase reagent (Zhong-
shan Co., Beijing, China) was applied at 37°C for 15 min-
Table 1: Summarized patient data
Characteristics Number %
Number of patients 61
Age of diagnosis (years)
Range 31–72
Median 47
Histology
Fibroadenoma 10 16.4
Hyperplastic adenosis/Fibroadenoma 10 16.4
Invasive ductal 31 50.8
Invasive lobular 4 6.6
Invasive ductal-lobular 6 9.8
Stage (breast carcinoma)
I6 1 4 . 6
II 24 58.5
III 8 19.5
IV 3 7.3
Estrogen receptors (only for breast carcinoma)
Negative 22 53.7
Positive 19 46.3
Progesterone receptors (only for breast carcinoma)
Negative 24 58.5
Positive 17 41.5
ErbB2 receptors (only for breast carcinoma)
Negative 23 56.1
Positive 18 43.9BMC Cancer 2006, 6:298 http://www.biomedcentral.com/1471-2407/6/298
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utes and sections were again washed in PBS. The color was
developed by a 7-minute incubation with 3,3'-diami-
nobenzidine (DAB) solution and the sections were weakly
counterstained with hematoxylin, washed, dehydrated
with alcohol and xylene and mounted with coverslips.
Omission of the primary antibody and substitution by
nonspecific immunoglobulin at the same concentration
were used as negative controls. For ER, PR, and ErbB2
staining, sections were stained with the ER/PR/ErbB2
Immunohistochemistry Test Kit (Zhongshan Co., Beijing,
China), which includes the mouse monoclonal antibod-
ies against human ER, PR, and ErbB2 proteins.
Assessment of Fra-1, ER, PR and ErbB2 expression
Fra-1 expression is purely nuclear or mixed nuclear and
cytoplasmic. Nuclear reactivity was scored as high (>75%
cell positive) or low (<75% cell positive). Cytoplasmic
reactivity, when present (positive) was scored as high
(strong staining) and low (weak staining). The percentage
of tumor cells showing nuclear or cytoplasmic Fra-1 reac-
tivity was recorded semi-quantitatively at ×400 magnifica-
tion after examining the entire histologic section. ER and
PR staining was scored in a minimum of 300 histologi-
cally identified neoplastic cells, showing nuclear reaction.
Tumors with positive ER or PR nuclear staining in >10%
of tumor cells were defined as ER or PR positive, respec-
tively. For ErbB2 protein, immunostainings were scored as
strong (2++ and 3+++), weak or negative (0 and 1+)
according to the rate of labelled tumor cells and the mem-
brane staining intensity. The ErbB2 status was further clas-
sified as overexpressed including 2++ and 3+++ (positive)
or not significantly expressed (negative).
Statistical analysis
Data were analyzed using standard statistical software
SPSS version 13.0 (Chicago, Illinois) as previously
described. Fisher's Exact Test was used to determine the
significance of the association of the different factors.
Expression is defined as negative or positive staining and
staining pattern is defined as nuclear or cytoplasmic stain-
ing. P < 0.05 was considered significant.
Results
The results of the immunohistochemical study of 61
breast tissues (10 fibroadenomas, 10 hyperplastic adeno-
sis/fibroadenomas, 31 ductal carcinomas, 4 lobular carci-
nomas and 6 other types of breast carcinomas) are
summarized in Table 2. No staining was observed in the
absence of the primary antibodies or with nonspecific
immunoglobulin (Fig. 1A). Nuclear expression of Fra-1
was detected in all neoplastic tissues. In 85% of benign
tumors (17/20), the immunoreactivity for Fra-1-recogniz-
ing antibody was exclusively restricted to the nuclei. Fig.
1B shows that the nuclear immunoreactivity for Fra-1 was
identified mostly in the epithelial cells. Generally, the
nuclei of infiltrating inflammatory cells were not stained.
Moreover, the nuclear staining was not observed in all of
the epithelial cells. Fig. 1C and 1D shows the strong
immunostaining in fibroadenomas. In some ducts lined
with stratified epithelium, positive staining appeared
largely on the apical epithelial layer on the luminal aspect
as shown in Fig. 1D, but myoepithelial layer adjacent to
the acinal basement membrane was mostly negative.
However, the weak nuclear staining of some interlobular
stroma cells was also visible. In most cases (85%), the
immunoreactivity is present only in the nuclei. In three
cases (15%), focal unequivocal cytoplasmic staining was
also exhibited.
In contrast to fibroadenomas or hyperplastic adenosis/
fibroadenomas, strong positive nuclear staining for Fra-1
was easily seen in all types of breast carcinomas, either dif-
fuse (100% of the tumor cells positive) or focal (>75% of
the tumor cells positive). Moreover, a variable degree of
cytoplasmic staining was easily observed in ~90% breast
carcinomas, although the immunoreactivity in cytoplasm
was weaker than in nucleus. However, cytoplasmic locali-
zation of Fra-1 was rarely observed in adjacent peritu-
moural tissues. In normal epidermal tissues a weak
immunoreactivity was only restricted to the nucleus of
basal cell layer. In 56% of cases in breast carcinomas (23/
41), weak cytoplasmic immunostaining was observed
(Fig. 2A and 2B). It is noteworthy that in 34% cases (14/
Table 2: Fra-1 expression in benign and malignant breast tissues by immunohistochemistry
Histological type Fra-1 staining score*
Nuclear n cytoplasm n
Benign High 11 High 0
Low 9 Low 3
Negative 0 Negative 17
Carcinomas High 30 High 14
Low 11 Low 23
Negative 0 Negative 4
* Fra-1 staining score was as follows: for nuclear staining: high, >75% positive cells and strong staining; low, <75% positive cells and weak staining; 
for cytoplasmic staining: high, strong staining; low, weak staining.BMC Cancer 2006, 6:298 http://www.biomedcentral.com/1471-2407/6/298
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41), strong nuclear and cytoplasmic double staining was
very pronounced (Fig. 2C and 2D).
The accumulation of Fra-1 protein and the changes occur-
ring in its subcellular localization are illustrated in Figure
3A and 3B. Fra-1 protein immunostaining was usually
weak in normal tissues or well-differentiated adjacent per-
itumoural tissues and positive reactivity restricted to the
nucleus (Figure 3A). Whereas in poorer differentiated
region in the same section the expression of Fra-1 protein
was present in the nucleus and cytoplasm simultaneously
(Figure 3B). In addition, Fra-1 expression was observed in
all types of breast carcinomas.
The results provided in Table 3 showed an association
between the cytoplasmic expression of Fra-1 and breast
carcinoma. There was a significant relationship between
the cytoplasmic expression of Fra-1 and breast carcinomas
(P = 0.000). No inverse relationship between Fra-1 and ER
and PR protein levels was noticed in malignant tumors
(Table 4). The relative expression level of Fra-1 was not
correlated with the expression of ErbB2.
Discussion
A large group of oncogenes encode transcription factors.
The oncogenic transcription factors play critical role in
contributing to malignancy by altering programs of cell
growth, differentiation and development. Activation of
AP-1 has been implicated in the fundamental processes
The differential expression of Fra-1 protein in breast carcino- mas Figure 3
The differential expression of Fra-1 protein in breast carcino-
mas. Fra-1 protein immunostaining was weak in adjacent per-
itumoural tissues and positive reactivity restricted to nuclear 
(A), but strong in poorer differentiated region in the same 
section and positive reactivity presented in nuclear and cyto-
plasmic simultaneously (B). ×400 magnification.
A B
The immunohistochemical staining of Fra-1 in benign breast  tumors Figure 1
The immunohistochemical staining of Fra-1 in benign breast 
tumors. Paraffin-embedded tissue sections were prepared. Endog-
enous peroxidase activity was quenched using 3% hydrogen per-
oxide before immunohistochemical staining. The Streptavidin-
Biotin method was used to detect Fra-1 expression. The rabbit 
anti-human Fra-1 polyclonal antibody at a concentration of 5 μg/
ml in PBS was applied for 60 minutes at 37°C or overnight at 4°C. 
The sections were then incubated with biotinylated anti-rabbit 
antibody at 37°C for 15 minutes. The streptavidin peroxidase rea-
gent was applied at 37°C for 15 minutes. The color was developed 
by incubating with DAB solution. A, nonspecific immunoglobulin 
was used as a negative control. B, The nuclear immunoreactivity 
for Fra-1 was identified mostly in the epithelial cells of fibroadeno-
mas. C, The strong nuclear immunostaining was present in 
fibroadenomas. D, Positive staining appeared largely on the apical 
epithelial layer on the luminal aspect, but myoepithelial layer was 
mostly negative. ×400 magnification.
D C
B A
The immunohistochemical staining of Fra-1 in breast carcino- mas Figure 2
The immunohistochemical staining of Fra-1 in breast carcino-
mas. A and B, strong nuclear and weak cytoplastic immunos-
taining were observed in two representative invasive ductal 
carcinomas. C and D, Strong nuclear and cytoplasmic double 
staining was very pronounced in two representative invasive 
ductal carcinomas. E, nonspecific immunoglobulin was used 
as a negative control. ×400 magnification.
D C
B A
C
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occurring in mammalian cells. Promoters and enhancers
of many genes, whose expression is affected in cancer
development, bear TRE capable of binding the Fos and
Jun transcription factors. Recent reports have underlined
a crucial role of Fra-1 in the transformation of several cell
lines. For example, ectopic expression of Fra-1 in rat fibro-
blast cells induced tumorigenicity [25]. Fra-1 gene induc-
tion was required for establishment of the neoplastic
phenotype in retrovirally transformed rat thyroid cells
[31]. The overexpression of Fra-1 protein had also been
described in a variety of epithelial neoplasias, including
thyroid cancer [27], esophageal squamous carcinoma
[32], endometrial cancer [33] and prostate cancer [34] A
tight association of Fra-1 expression with highly invasive
breast cancer cell lines has been demonstrated. Fra-1 was
efficient for stimulating MMP-9, MMP-1, VEGF and cyclin
D1 production in MCF7 cells [23] and could induce the
expression of osteopontin (OPN), thrombospondin and
CD44 [35], suggesting that Fra-1 might influence cell pro-
liferation, invasion and angiogenesis. The effects of Fra-1
on motility and invasion have been observed in four
highly invasive and nine weakly invasive human breast
cancer cell lines by cDNA array technology. Among 24 dif-
ferentially expressed genes, Fra-1 expression level was sig-
nificantly enhanced in the highly invasive cells. Similar
results were found by cDNA array technology in 22
human mammary epithelial cell strains/lines (breast can-
cer cell lines and cells derived from primary or metastatic
breast cancers and reduction mammoplasties) [26]. Some
authors suggested that Fra-1 might be a valuable diagnos-
tic marker in breast cancer.
Fra-1 Expression at both mRNA and protein levels in
breast cancer tissues has been previously studied using
Northern blot and Western blot [36,37]. To further inves-
tigate the significance of Fra-1 in human breast cancer, the
expression of Fra-1 was investigated in this study by
immunohistochemistry with the anti-Fra-1 antibody in
neoplastic breast diseases ranging from benign fibroade-
noma to very aggressive undifferentiated carcinoma. The
correlations of Fra-1 expression with other indicators of
breast carcinoma prognosis (ER, PR and ErbB2 receptors)
were analyzed. All neoplastic breast tissues, either benign
or malignant breast tissues, were nuclear immunoreactive
for Fra-1-recognizing antibody, whereas tumor adjacent
normal tissues showed a much weaker nuclear immuno-
reactivity only restricted to some epithelial cells. The pat-
terns of Fra-1 expression by benign neoplastic cells were
predominantly nuclear. In only 3 of 20 cases of fibroade-
nomas or hyperplastic adenosis/fibroadenomas, nuclear
expression coexisted with weak cytoplasmic reactivity.
However, the nuclear/cytoplasmic concomitant immuno-
reactivity was observed in all types of breast carcinomas. A
clear shift in Fra-1 immunoreactivity, from an exclusively
Table 4: Correlation of Fra-1 cytoplasmic expression with other prognostic factors
Characteristics Cytoplasm Fra-1 expression P
Positive (%) Negative (%)
ER
negative 17 (77.3) 5 (22.7) 1.00
positive 15 (78.9) 4 (21.9)
PR
negative 21 (87.5) 3 (12.5) 0.128
positive 11 (35.3) 6 (64.7)
HER-2
negative 18 (78.3) 5 (21.7) 1.00
positive 14 (77.8) 4 (22.2)
* The positive cytoplasmic immunohistochemical reactivity of Fra-1 in breast carcinomas includes strong and weak staining. The ErbB2 status was 
classified as positive (2++ and 3+++) and negative (1+ and 0).
Table 3: Correlation of Fra-1 cytoplasmic expression with benign and malignancy
Tumor Cytoplasm Fra-1 expression P value
Positive(%) Negative (%)
Benign 3 (15.0) 17 (85.0) 0.000
Malignancy* 37 (90.2) 4 (9.8)
* The positive cytoplasmic immunohistochemical reactivity of Fra-1 in breast carcinomas includes strong and weak staining.BMC Cancer 2006, 6:298 http://www.biomedcentral.com/1471-2407/6/298
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nuclear to a simultaneous nuclear and cytoplasmic locali-
zation was noticed in ~90% of breast carcinomas. We can
not exclude a slight increase in Fra-1 expression not
detectable by immunohistochemistry. The data indicate
that the expression pattern and intensity of Fra-1 proteins
are correlated with epithelial cell oncogenesis.
A negative correlation of ER/PR and Fra-1 expression was
observed in breast cancer cell lines. In breast cancer tis-
sues, Fra-1 was found correlated with ER status in one
study [37]. The high Fra-1 expression and phosphoryla-
tion in ER-negative cells appeared to take place only in
culture conditions, since the phosphorylated bands were
undetectable in clinical tumor tissue from both ER-posi-
tive and ER-negative carcinomas [37]. In another study,
an inverse correlation of Fra-1 level with a progesterone
receptor isoform PR-B expression was observed [38].
However, the correlations of Fra-1 expression with ER, PR
and ErbB2 were not found in our study. The further inves-
tigation is still needed.
Fra-1 lacks a transcriptional transactivation domain and it
is thought, in partnership with c-Jun, to drive the expres-
sion of genes [35]. Its overexpression results in the tran-
scription of progression-associated genes and induction
of epithelial mesenchymal transition [22,25]. The recent
evidence has indicated a potential role for Fra-1 in abnor-
mal differentiation and transformation of lung cells
[19,39]. However, the role played by Fra-1 in malignancy
remains unclear. It is known that many transcription fac-
tors shuttle between the nucleus and cytoplasm. The syn-
thesis of Fra-1 is supposed to start in the cytoplasm.
However when it was overexpressed, nuclear import
might be hampered. Saturation of a nuclear import mech-
anism, leading to a persistent high cytoplasmic concentra-
tion of the proteins, may also play a role in the process of
breast carcinogenesis.
The recent study showed that nuclear p21Cip1/WAF1
translocates to the cytoplasm and this translocation event
is accompanied by resistance to various apoptotic stimuli
[40]. The non-transcriptional mechanism of Fra-1
remains to be further demonstrated.
Conclusion
In summary, our data by immunohistochemical analysis
of breast tissues, including benign and malignant breast
carcinomas, reveal that Fra-1 protein accumulation in the
cytoplasm may play an important role in human breast
carcinogenesis. These data may highlight the significance
of therapy based on the blockage of Fra-1 functions of
breast cancers.
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